Summary by Moomoo AI
On May 7, 2024, New Enterprise Associates 15, L.P. (NEA 15), along with its associated entities and managers, filed an amendment to Schedule 13D with the SEC, indicating a change in their beneficial ownership of Reneo Pharmaceuticals, Inc. common stock. The filing, which amends the original Schedule 13D filed on April 23, 2021, reports that the group's beneficial ownership has decreased by more than 1% due to an increase in the number of outstanding shares of Reneo Pharmaceuticals. The group collectively owns 4,785,494 shares, representing 14.3% of the company's class of common stock. The filing was executed by managing partners Anthony A. Florence, Jr. and Mohamad Makhzoumi, among others, and was facilitated by attorney-in-fact Zachary Bambach. The decrease in ownership percentage is attributed to the dilution effect of new shares issued by Reneo Pharmaceuticals, rather than the sale of shares by the reporting persons.